Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate
AssigneeSuven Life Sciences Limited
InventorsRamakrishna Nirogi, Rama Sastri Kambhampati, Anil Karbhari Shinde, Venkateswarlu Jasti
Life of this patent
Estimating the term…
Abstract
A process suitable for adoption to large scale manufacture of 1-[(2-bromophenyl-sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate, which is a selective 5-HT6 receptor antagonist intended for the symptomatic treatment of Alzheimer's disease and other disorders of memory and cognition like Attention deficient hyperactivity, Parkinson's and Schizophrenia.
Claims12
A process suitable for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate of formula (I),
- which comprises:
- Step (i):
- reacting 1-methylpiperazine of formula 1
- in presence of acetic acid and aqueous formaldehyde of formula 2
- HCHO 2
- at a temperature in the range of 15° C. to 35° C. for a period of 1.5 hours to 2.5 hours to obtain Mannich adduct;
- Step (ii):
- reacting the Mannich adduct with 5-methoxyindole of formula 3
- in presence of methanol at a temperature in the range of 15° C. to 40° C. for a period of 2.5 hours to 3.5 hours to obtain 5-methoxy-3-[(4-methyl-1-piperazinyl) methyl]-1H-indole of formula 4;
- Step (iii):
- crystallizing 5-methoxy-3-[(4-methyl-1-piperazinyl) methyl]-1H-indole of formula 4 in toluene by heating the solution to 85° C.-95° C. for a period of 1 hour, followed by cooling the solution to 10° C.-15° C. for the period of 3 hours;
- Step (iv):
- recrystallizing 5-methoxy-3-[(4-methyl-1-piperazinyl) methyl]-1H-indole of formula 4 in toluene by heating the solution to 95° C.-105° C. for a period of 2 hours, followed by cooling the solution to 10° C. 15° C. for a period of 3 hours;
- Step (v):
- reacting the above obtained crystalline 5-methoxy-3-[(4-methyl-1-piperazinyl) methyl]-1H-indole of formula 4 with 2-bromobenzenesulfonyl chloride of formula 5;
- in presence of tetrahydrofuran and potassium hydroxide at a temperature in the range of 20° C. to 40° C. for a period of 3.5 hours to 4.5 hours to obtain 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole of formula 6;
- Step (vi):
- converting 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3[(4-methyl-1-piperazinyl)methyl]-1H-indole of formula 6 in presence of ethanol and methanesulfonic acid at a temperature in the range of 15° C. to 35° C. for a period of 18 hours to 24 hours to obtain 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate of formula 7;
- Step (vii):
- converting 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate of formula 7 in presence of aqueous ethanol and carbon slurry at a temperature in the range of 75° C. to 85° C. for a period of 0.5 hour-1.5 hours to obtain 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate of formula (I).
Dependencies are inferred from the claim text.